Chimeric Therapeutics
Chimeric - Model CHM 1101 (CLTX CAR T) -T Cell Derived Autologous Therapies
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting domain.
Most popular related searches
T-cell therapy
T-cell
cell therapy
car-t cell
solid tumor
clinical trial
autologous cell therapy
preclinical trial
preclinical modeling
tumor activity
- CHM 1101 has been shown to more specifically and broadly target GBM cells than other immunotherapy targets like HER2, EGFR and IL13, through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2)
- CHM 1101 demonstrated excellent preclinical safety with no off tumour recognition of normal human or murine cells or tissues in preclinical models, consistent with the documented safety of administering CLTX containing agents in humans
- CHM 1101 demonstrated potent anti-tumour activity in vivo with significantly improved survival in mice
Based upon evidence of CLTX binding in other solid tumours, preclinical studies are currently ongoing to determine the potential of CHM 1101 in solid tumours such as melanoma, colorectal cancer and prostate cancer.